DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Tannir NM, McDermott DF, Escudier B. et al.
Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab 1 ipilimumab (N1I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma aRCC.
J Clin Oncol 2020;
38: 609
Access:
We do not assume any responsibility for the contents of the web pages of other providers.